RemeGen Co (HKSE:09995) Long-Term Capital Lease Obligation : HK$81.7 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Long-Term Capital Lease Obligation?

RemeGen Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$81.7 Mil.

RemeGen Co's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 (HK$106.0 Mil) to Sep. 2023 (HK$0.0 Mil) but then increased from Sep. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$81.7 Mil).

RemeGen Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$61.6 Mil) to Dec. 2022 (HK$117.1 Mil) but then declined from Dec. 2022 (HK$117.1 Mil) to Dec. 2023 (HK$81.7 Mil).

RemeGen Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for RemeGen Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Long-Term Capital Lease Obligation Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.19

55.22

61.62

117.12

81.68

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial									117.12	106.02	-	81.68	-

RemeGen Co (HKSE:09995) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

RemeGen Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines